Rachel Haurwitz (Caribou)

Ab­b­Vie taps Jen­nifer Doud­na start­up for li­cens­ing deal worth up to $300M for 2 'off-the-shelf' CRISPR-edit­ed CAR-Ts

“Off-the-shelf” CAR-Ts have emerged as a hot-tick­et tar­get in next-gen on­col­o­gy R&D, with Big Phar­mas plac­ing big down pay­ments on nov­el tech. Now, a Cal­i­for­nia biotech play­er found­ed by one of the CRISPR move­ment’s most promi­nent mouth­pieces has added ma­jor drug­mak­er Ab­b­Vie as a team­mate.

Ab­b­Vie will pay Cari­bou Bio­sciences $40 mil­lion in up­front cash and $300 mil­lion in biobucks to de­vel­op two of the biotech’s al­lo­gene­ic CAR-T ther­a­pies, the part­ners said Wednes­day. The biotech will al­so be due roy­al­ty pay­ments for any fu­ture com­mer­cial as­sets.

Jen­nifer Doud­na

Cari­bou, co-found­ed by CRISPR maven Jen­nifer Doud­na and head­ed by one of Doud­na’s acolytes, Rachel Hau­r­witz, us­es hy­brid DNA/RNA edit­ing tech­nol­o­gy dubbed chRD­NA — pro­nounced “chardon­nay” for the wine drinkers — the biotech be­lieves can stop off-tar­get edit­ing com­mon to cur­rent CRISPR ap­pli­ca­tions.

Ab­b­Vie will have the op­tion to pay an ex­tra fee for ac­cess to two ad­di­tion­al CAR-T pro­grams, Cari­bou said.

On a call with End­points News, Hau­r­witz de­clined to com­ment on what drew Ab­b­Vie to Cari­bou’s tech­nol­o­gy or what ther­a­peu­tic ar­eas the drug­mak­er want­ed to tar­get with the po­ten­tial CAR-Ts. That’s not un­usu­al: Ab­b­Vie is usu­al­ly cagey with its ear­ly de­vel­op­ment deals.

In­stead, the young CEO — just 35 and one of the lead­ing voic­es in the CRISPR move­ment — tout­ed her plat­form’s po­ten­tial to re­work cur­rent lim­i­ta­tions on al­lo­gene­ic CAR-Ts, in­clud­ing pa­tients’ im­mune sys­tems re­ject­ing donor cells. The ef­fects could be most ap­par­ent, how­ev­er, in man­u­fac­tur­ing, a chron­i­cal­ly ex­pen­sive and time con­sum­ing process for CAR-Ts.

Un­like tra­di­tion­al CAR-Ts, which re­quire com­pa­nies to re-en­gi­neer pa­tients cells that are of­ten dam­aged af­ter chemother­a­py and past ther­a­pies, al­lo­gene­ic ther­a­pies can use donor cells that are health­i­er and faster to ad­min­is­ter.

“It re­al­ly has tremen­dous ad­van­tages from a tim­ing per­spec­tive,” Hau­r­witz said. “There are of course re­al­ly nice ad­van­tages in terms of qual­i­ty and cost of goods.”

Al­lo­gene­ic cell ther­a­pies are among the hottest fields in next-gen on­col­o­gy, and Ab­b­Vie — one of the four largest drug­mak­ers on earth — is seek­ing to take a mod­est-sized bet out on Cari­bou’s stout rep­u­ta­tion and clin­i­cal po­ten­tial.

The biotech has two lead pro­grams: CB-010, an an­ti-CD19 CAR-T that deletes PD-1 cur­rent­ly in a Phase I tri­al, and CB-011, a pre­clin­i­cal as­set that hopes to uti­lize “im­mune cloak­ing” to avoid the hu­man im­mune sys­tem, Hau­r­witz said.

The DCT-OS: A Tech­nol­o­gy-first Op­er­at­ing Sys­tem - En­abling Clin­i­cal Tri­als

As technology-enabled clinical research becomes the new normal, an integrated decentralized clinical trial operating system can ensure quality, deliver consistency and improve the patient experience.

The increasing availability of COVID-19 vaccines has many of us looking forward to a time when everyday things return to a state of normal. Schools and teachers are returning to classrooms, offices and small businesses are reopening, and there’s a palpable sense of optimism that the often-awkward adjustments we’ve all made personally and professionally in the last year are behind us, never to return. In the world of clinical research, however, some pandemic-necessitated adjustments are proving to be more than emergency stopgap measures to ensure trial continuity — and numerous decentralized clinical trial (DCT) tools and methodologies employed within the last year are likely here to stay as part of biopharma’s new normal.

Onno van de Stolpe, Galapagos CEO (Thierry Roge/Belga Mag/AFP via Getty Images)

Gala­pa­gos chops in­to their pipeline, drop­ping core fields and re­or­ga­niz­ing R&D as the BD team hunts for some­thing 'trans­for­ma­tive'

Just 5 months after Gilead gutted its rich partnership with Galapagos following a bitter setback at the FDA, the Belgian biotech is hunkering down and chopping the pipeline in an effort to conserve cash while their BD team pursues a mission to find a “transformative” deal for the company.

The filgotinib disaster didn’t warrant a mention as Galapagos laid out its Darwinian restructuring plans. Forced to make choices, the company is ditching its IPF molecule ’1205, while moving ahead with a Phase II IPF study for its chitinase inhibitor ’4617.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 104,800+ biopharma pros reading Endpoints daily — and it's free.

Stéphane Bancel, Getty

Mod­er­na CEO brush­es off US sup­port for IP waiv­er, eyes more than $19B in Covid-19 vac­cine sales in 2021

Moderna is definitively more concerned with keeping pace with Pfizer in the race to vaccinate the world against Covid-19 than it is with Wednesday’s decision from the Biden administration to back an intellectual property waiver that aims to increase vaccine supplies worldwide.

In its first quarter earnings call on Thursday, Moderna CEO Stéphane Bancel shrugged off any suggestion that the newly US-backed intellectual property waiver would impact his company’s vaccine or bottom line. Still, the company’s stock price fell by about 9% in early morning trading.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 104,800+ biopharma pros reading Endpoints daily — and it's free.

Angela Merkel (AP Photo/Michael Sohn)

Covid-19 roundup: Pfiz­er sub­mits vac­cine for full ap­proval; Merkel op­pos­es Biden pro­pos­al to sus­pend IP for vac­cines

Pfizer and BioNTech said Friday that they’ve submitted a biologics license application to the FDA for full approval of their mRNA vaccine for those over the age of 16.

How long it will take the FDA to decide on the BLA will be set once it’s been formally accepted by the agency.

Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, previously told Endpoints News that the review of the BLA should take between three and four months, but it may be even faster than that.

UP­DAT­ED: EMA safe­ty com­mit­tee seeks more in­fo on heart in­flam­ma­tion fol­low­ing Pfiz­er Covid-19 vac­cine

The European Medicines Agency’s safety committee said Friday that it’s aware of cases of inflammation of the heart muscle and inflammation of the membrane around the heart, mainly reported following vaccination with Pfizer’s Covid-19 vaccine, known in Europe as Comirnaty.

“There is no indication that these cases are due to the vaccine,” the EMA’s Pharmacovigilance Risk Assessment Committee said.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 104,800+ biopharma pros reading Endpoints daily — and it's free.

As­traZeneca caps PD-L1/CT­LA-4/chemo com­bo come­back with OS win. Is treme­li­mum­ab fi­nal­ly ready for ap­proval?

AstraZeneca’s closely-watched POSEIDON study continues to be the rare bright spot in its push for an in-house PD-L1/CTLA-4 combo.

Combining Imfinzi and tremelimumab with physicians’ choice of chemotherapy helped patients with stage IV non-small cell lung cancer live longer, the company reported — marking the first time the still-experimental tremelimumab has demonstrated an OS benefit.

For AstraZeneca and CEO Pascal Soriot, the positive readout — which is devoid of numbers — offers much-needed validation for the big bet they made on Imfinzi plus tremelimumab, after the PD-L1/CTLA-4 regimen failed multiple trials in head and neck cancer as well as lung cancer.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 104,800+ biopharma pros reading Endpoints daily — and it's free.

Ron DePinho (file photo)

A 'fly­over' biotech launch­es in Texas with four Ron De­Pin­ho-found­ed com­pa­nies un­der its belt

In his 13 years at Genzyme, Michael Wyzga noticed something about East Coast drugmakers. Execs would often jet from Boston or New York to San Francisco to find more assets, and completely miss the work being done in flyover states, like Texas or Wisconsin.

“If it doesn’t come out of MGH or MIT or Harvard, probably not that interesting,” he said of the mindset.

Now, he and some well-known industry players are looking to change that, and they’ve reeled in just over $38 million to do it.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 104,800+ biopharma pros reading Endpoints daily — and it's free.

An­oth­er failed tri­al for Or­p­hazyme's 'pipeline-in-a-pro­duc­t' leaves shad­ow on drug's fu­ture

The tumultuous ride for Orphazyme continued on Friday as the company announced that a pivotal trial for its lead drug arimoclomol failed yet again, this time in the treatment of ALS, seeding doubt in a drug that had recently been cleared by the FDA for priority review. The latest failure casts a darker shadow on the upcoming decision despite Orphazyme’s upbeat outlook.

In a statement, the Danish biotech announced that the drug did not meet its primary or secondary endpoints evaluating function and survival. But the company has not announced any data surrounding the failure, instead saying that it will publish the complete results later this year.

In­cyte ponies up $12M to set­tle char­i­ty foun­da­tion kick­back claims; US ex­er­cis­es op­tion for more dos­es of mon­key­pox vac­cine

One in a string of lawsuits targeting copay charity foundations, the DOJ has been hunting drugmaker Incyte for what prosecutors alleged was a kickback scheme to court patients. Now, Incyte is clearing its name.

Incyte will shell out $12.6 million to settle claims it funneled funds through a charity foundation to cover federal copays for patients taking its JAK inhibitor Jakafi, the DOJ said this week.